Korruption torjunta osana yritysvastuuta

#ThinkingAhead

Dittmar & Indreniuksen ja Terveysteknologia ry:n yhteistyössä toteuttaman webinaarisarjan kolmannessa osassa Juli Mansnérus ja Hanna-Mari Manninen puhuvat korruption torjunnan merkityksestä osana vastuullista yritystoimintaa.

Webinaarissa käsitellään muun muassa seuraavia aiheita:

  • Vastuullinen yritystoiminta ja korruption torjunta: Miksi se on tärkeää?
  • Mitä korruptio on?
  • Miten toimia käytännössä, ja onko Healthtech-yrityksillä jotakin erityistä huomioitavaa?

Webinaari
tiistai 17.5.2022, klo 10.00 – 11.00

Jos et ole saanut kutsua tilaisuuteen ja haluaisit osallistua, voit olla yhteydessä:
[email protected]

Tilaisuutemme ovat ensisijaisesti tarkoitettu asiakkaillemme ja muille sidosryhmillemme.

The webinar is in Finnish.

More by the same author

The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

The European Parliament and the Council reach an agreement on European Health Data Space!

Towards a stronger European Health Union On March 15, 2024, the European Parliament and the Belgian Presidency of the Council reached a provisional political agreement on the European Health Data Space (EHDS) which is considered one of the central building blocks towards a stronger European Health Union. The upcoming EHDS aims to harness the full potential offered by the sharing, use, and re-use of health data, while ensuring full compliance with the data protection standards in the EU. This marks a significant milestone in the EU’s health data regulation.

Commission proposes extension of IVDR transition periods for legacy products

The European Commission has on 23 January 2024 announced a proposal for an extension to the transition period for the forthcoming In Vitro Diagnostic Medical Devices Regulation (IVDR). The aim is to ensure patient care by improving the availability of these essential healthcare products. In addition, the Commission also proposes measures to enable and accelerate a gradual roll out of EUDAMED, a database that will contain information about all medical devices and in vitro diagnostics (IVDs) placed on the EU market. The mandatory use of finalised parts of EUDAMED will support all key players in the implementation of the regulatory framework and enhance transparency for the public.

Latest insights

Are Finnish Lawyers the Happiest in the World?

Article / 4 Apr 2024
Reading time 2 minutes

Implementing the Data Act without Clashing with the GDPR?

Article / 4 Apr 2024